CompletedPhase 3NCT00004031
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Patrick J. Stiff, MD, MDLoyola University
- Intervention
- rituximab(biological)
- Enrollment
- 397 enrolled
- Eligibility
- 15-65 years · All sexes
- Timeline
- 1997 – 2013
Study locations (15)
- Oregon Health & Science University, Portland, Oregon, United States
- Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada
- Cross Cancer Institute at University of Alberta, Edmonton, Alberta, Canada
- CancerCare Manitoba, Winnipeg, Manitoba, Canada
- Moncton Hospital, Moncton, New Brunswick, Canada
- Doctor H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada
- Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada
- Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
- London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
- Odette Cancer Centre at Sunnybrook, Toronto, Ontario, Canada
- Hopital Notre-Dame du CHUM, Montreal, Quebec, Canada
- Hopital Du Sacre-Coeur de Montreal, Montreal, Quebec, Canada
- Centre Hospitalier Universitaire de Quebec, Québec, Quebec, Canada
- Hopital du Saint-Sacrement - Quebec, Québec, Quebec, Canada
- Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Collaborators
National Cancer Institute (NCI) · Cancer and Leukemia Group B · Eastern Cooperative Oncology Group · NCIC Clinical Trials Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00004031 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha